Compare NTRB & GRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTRB | GRF |
|---|---|---|
| Founded | 2016 | 1989 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Industrial Specialties | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.1M | 43.9M |
| IPO Year | N/A | N/A |
| Metric | NTRB | GRF |
|---|---|---|
| Price | $3.54 | $10.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 11.6K | 2.1K |
| Earning Date | 04-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.70% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.16 |
| Revenue | N/A | N/A |
| Revenue This Year | $30.17 | N/A |
| Revenue Next Year | $3,394.36 | N/A |
| P/E Ratio | ★ N/A | $9.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.42 | $9.05 |
| 52 Week High | $11.68 | $11.85 |
| Indicator | NTRB | GRF |
|---|---|---|
| Relative Strength Index (RSI) | 40.43 | 51.19 |
| Support Level | $3.53 | $10.43 |
| Resistance Level | $4.50 | $11.00 |
| Average True Range (ATR) | 0.29 | 0.18 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 27.27 | 74.63 |
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.